

# Can approaches for collecting participant-reported harms in malaria clinical drug trials be harmonised?



Elizabeth Allen, University of Cape Town, South Africa



## Adverse events: the more you search, the more you find

Ioannidis et al. Ann Intern Med 2006

Patients given a <u>checklist</u> of 53 possible adverse events reported 20-fold more than those who answered <u>open-ended questions</u>

Forgot

Confused by question

WHY?

Cultural issues

Is there more data? Which data are valid? Does it matter?

Bent et al. Brief Communication: Better Ways To Question Patients about Adverse Medical Events: A Randomized, Controlled Trial. *Ann Intern Med.* 2006



## **ACTc** sub-studies

#### Mixed method study nested in 2 similar ACTc trials

- Identify factors shaping reports of medical history, adverse events, non-study meds by participants enrolled in ARV/AM trials
- Inform practices for improving reporting in these contexts



Explore how these data are obtained





### Delphi study

Consensus on the appropriate methods and/or tools to use



## Mixed-method study

#### South Africa (n=18)

- In/out-patient
- HIV+/ARV+/malaria-


#### Tanzania (n=80)

- Out-patient
- Combinations of HIV+/ARV+/malaria±

Coartem® twice daily x 3 days

In-depth interviews/FGDs with those reporting differently between general enquiry/checklist

- Narrative
- Explanation



Medical history, previous & concomitant treatments, change in health post-dose

2 occasions (pre-dose & 4-7 days post-dose)



## Mixed-method study cont.

#### Results

Overall increase in reports from general enquiry, through checklists, to in-depth interview

	South Africa			Tanzania			
	Medical	Adverse	Meds	Medical	Adverse	Meds	
	histories	events		histories	events		
Number of reports by	4	23	17	285	6	196	
general enquiry*							
Additional number of	8 (200.0)	20 (87.0)	23 (135.3)	245	1 (16.7)	2 (91.3)	
reports by checklists				(86.0)			
(% change from							
general enquiry)*							
Additional number of	4 (33.3)	1 (2.3)	4 (10.0)	15 (2.8)	0 (0)	9 (4.5)	
reports by interview							
**(% change from							
general enquiry and							
checklist)							


\* All participants in the sampling frame attending both visits (South Africa n=16, Tanzania n=76)
\*\*Subset of participants who took part in in-depth interviews (South Africa n=11, Tanzania n=16)

Checklists facilitated recognition of health issues/meds, & consideration of what to report. But did not overcome all barriers ......

Certain information not reported initially as participants **forgot** or they had **low significance** (normalised, gauged against other experiences)

Information could be **not relevant** (South Africa: trial-related, Tanzania: illness-related), or have **negative consequences** (South Africa: withdrawal from trial, Tanzania: against hospital 'rules')

Narratives suggested inability to name medicines, questions inferior to blood tests





## Mixed-method study cont.

Questioning methods/trial contexts influence detection of participant-reported safety data

Limitation to assessments and pooling of data

#### For exploration:

- Explain that checklists, if used, are examples, answers as important as tests
- Counsel against perceived punishment for non-reporting
- Find optimal phraseology
- Harmonisation?




Figure 1: Diagram of trial participants' narrative responses



## Online survey of malaria trialists

- E-mails, newsletters, flyers
- To capture detail, rationale and application of methods within various study designs and populations (last study conducted)
- Closed responses analysed by proportions, open responses by repeating ideas and underlying concepts


A snapshot, and sensitisation of a community of researchers for future discussions (Delphi)





## Survey cont.

#### Results

- 52 respondents from 25 countries, 87% at investigational site,
  75% reporting about intervention study
- Interventional studies 31% general/structured combination (open and specific questions), 18% general only,
   26% structured only
- A minority incorporated pictorial tools







Rationale for	Example quotes from survey respondents	Question method used in the study			
questioning method (n=28)		General enquiry only	Structured enquiry only	General & structured enquiry combined	Addition of other tools*
Standardization of assessments or data capture (including historical use of a method in the research group)	"A systematic approach based on pharmacovigilance procedures developed by our collaborators"  "We are used to that"	х	х	х	
Specificity of data sought (seeking information about particular adverse events, malaria symptoms or drugs)	"We wanted to find out about specific symptoms and adverse effects" "The named drug questions targeted drugs of special interest"	x	x	x	
Comprehensiveness of data sought (participant guidance, report clarification, overcoming barriers to reporting such as poor recall or ability to name medicines)	"To provide a clear understanding about what investigators are looking for and to be sure they capture all complaints from study participants"  "To get more information which may have been missed during the initial interview"		x	x	x
Avoidance of suggestion	"Keeping questions open and not leading so that only events significant to the patient are reported"	х		х	
Feasibility	"A simple screen [as the] main focus of the study was not safety/tolerability"  "Appears simple and not complex"	x	x	x	
Understand participants' perceptions about health	"[To] know if [symptoms] are related to chronic disease or traditional belief"		x	x	



## Survey cont.

#### Results cont.

- Range of methods
- Overlap in use of different questioning methods to fulfill same rationale
- Most respondents considered approach they used as optimal, though several reconsidered this during the survey (on reflection?)
- 5 felt methods should depend on study design



## Can approaches for collecting participant-reported harms in malaria clinical drug trials be harmonised?

#### Delphi study ongoing

- Present summary results & relevant literature
- Suggest then rate questioning methods ito importance/feasibility
- Revise opinion if deviate from group



Potentially a basket of options for use/testing



#### Is there more data? Which data are valid? Does it matter?

- Complex field (designs/contexts, triadic communications, validation)
- Cost of formative/technical work
- Sensitivity more important where risk:benefit & impact on adherence are greater
- Important to describe methods used in publications
- Questions unlikely to be "exhaustive and feasible"
- User-friendly data collection tools/databases







## Thank you!

www.actconsortium.org/safetydatacollection



## Thank you for joining us!

Recording will be shared. Please ensure you are on our mailing list:

www.actconsortium.org/newsletter

For any questions or comments, contact debora.miranda@lshtm.ac.uk

